Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 118

Results For "ENT"

9934 News Found

Fire accident at Parmax Pharma’s plant
News | December 09, 2023

Fire accident at Parmax Pharma’s plant

There has been no loss or injury to human life


Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug
News | December 07, 2023

Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug

Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya


Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin Tablets
Drug Approval | December 07, 2023

Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin Tablets

This product will be manufactured by Indoco Remedies at their manufacturing facility located at Goa


Sun Pharmaceutical inks licensing agreement with Aclaris Therapeutics
News | December 06, 2023

Sun Pharmaceutical inks licensing agreement with Aclaris Therapeutics

The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties


India joins Executive Committee of Codex Alimentarius Commission
Policy | December 03, 2023

India joins Executive Committee of Codex Alimentarius Commission

India had proposed for setting up the global standards for millets


AIIA initiates training programme on latent tuberculosis infections
Healthcare | December 02, 2023

AIIA initiates training programme on latent tuberculosis infections

The workshop is specially curated for Ayurvedic medical officers from Delhi and Haryana


Developing entrepreneurship in Ayush Sector is a priority area: Ayush Minister
Policy | December 02, 2023

Developing entrepreneurship in Ayush Sector is a priority area: Ayush Minister

Global Ayurveda Festival organising in Thiruvananthapuram from 1st to 5th December


Strides launches Icosapent Ethyl Acid Soft Gel capsules in partnership with Amneal
News | December 02, 2023

Strides launches Icosapent Ethyl Acid Soft Gel capsules in partnership with Amneal

The product has been in-licensed from Strides and will be commercialized by Amneal


Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial
Clinical Trials | November 29, 2023

Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial

Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease